Home
Search
Study Topics
Glossary
|
Study 9 of 155 for search of: | Iran, Islamic Republic of |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsored by: |
Shaheed Beheshti Medical University |
---|---|
Information provided by: | Shaheed Beheshti Medical University |
ClinicalTrials.gov Identifier: | NCT00370201 |
This clinical trial will test the efficacy and safety of oral colchicine in prevention of proliferative vitreoretinopathy (PVR) in cases of rhegmatogenous retinal detachment
Condition | Intervention | Phase |
---|---|---|
Rhegmatogenous Retinal Detachment |
Drug: colchicine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Iran, Islamic Republic of | |
Hamid Ahmadieh,MD | |
Tehran, Iran, Islamic Republic of, 16666 |
Principal Investigator: | Hamid Ahmadieh, MD | Ophthalmic Research Center of Shaheed Beheshti Medical University |
Study ID Numbers: | 8259 |
Study First Received: | August 30, 2006 |
Last Updated: | October 6, 2006 |
ClinicalTrials.gov Identifier: | NCT00370201 |
Health Authority: | Iran: Ethics Committee |
retinal detachment proliferative vitreoretinopathy |
Retinal Detachment Eye Diseases Colchicine Vitreoretinopathy, Proliferative Retinal Diseases |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Mitosis Modulators Tubulin Modulators |
Antimitotic Agents Antirheumatic Agents Gout Suppressants Pharmacologic Actions |